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The filoviruses, Ebola (EBOV) and Marburg (MARV), are potential global health threats, which cause deadly hemorrhagic fevers.
Although both EBOVand MARV logarithmically replicate in dendritic cells (DCs), these viruses do not elicit DC cytokine secretion and fail
to activate and mature infected DCs. Here, we employed virus-like particles (VLPs) of EBOV and MARV to investigate whether these
genome-free particles maintain similar immune evasive properties as authentic filoviruses. Confocal microscopy indicated that human
myeloid-derived DCs readily took up VLPs. However, unlike EBOVand MARV, VLPs induced maturation of DCs including upregulation of
costimulatory molecules (CD40, CD80, CD86), major histocompatibility complex (MHC) class I and II surface antigens, and the late DC
maturation marker CD83. The chemokine receptors CCR5 and CCR7 were also modulated on VLP-stimulated DCs, indicating that DC could
migrate following VLP exposure. Furthermore, VLPs also elicited DC secretion of the pro-inflammatory cytokines TNF-a, IL-8, IL-6, and
MIP-1a. Most significantly, in stark contrast to DC treated with intact EBOVor MARV, DC stimulated with EBOVor MARV VLPs showed
enhanced ability to support human T-cell proliferation in an allogenic mixed lymphocyte response (MLR). Thus, our findings suggest that
unlike EBOV and MARV, VLPs are effective stimulators of DCs and have potential in enhancing innate and adaptive immune responses.
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Introduction mortality rates, significant transmissibility of disease, and aThe filoviruses, Ebola (EBOV) andMarburg (MARV), are
nonsegmented, negative-strand RNA viruses that belong to
the family Filoviridae. Filoviruses cause severe and often
fatal hemorrhagic fever in humans and nonhuman primates
(Lee and Henderson, 2001; Thacker, 2003; Whitfield, 2003).
Natural outbreaks have been limited, but are currently on the
rise (http://www.who.int/disease-outbreaks-news/disease/
bydisease.htm). In sizable outbreaks, human mortality rates
have approached 90% for EBOV and 70% for MARV
(Bertherat et al., 1999; Feldmann and Klenk, 1996). High0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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ruses a serious threat to public health. At this time, there are
no approved vaccines or therapeutics for treating or prevent-
ing EBOVand MARV infections. Hence, there is significant
concern that these highly pathogenic viruses may be used as
agents of mass casualty or bioterrorism.
The filovirus genome is 19 kb long, consisting of seven
structural proteins and one nonstructural protein (Sanchez et
al., 2001). Four of the viral proteins nucleoprotein (NP),
viral proteins VP35, VP30, and the RNA-dependent RNA
polymerase (L) are necessary for replication and transcrip-
tion of viral RNA (Muhlberger et al., 1999), although
glycoprotein (GP), VP40, and VP24 encode for mem-
brane-associated virion proteins (Sanchez et al., 2001).
The additional nonstructural EBOV protein is a secreted
truncated form of the envelope glycoprotein (sGP) generated
by reading of unedited mRNA (Feldmann and Klenk, 1996).
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surface and it appears to be the principal, but probably not
the only, mediator of protective immune responses (Hevey et
al., 1998; Wilson et al., 2000). One of the obstacles in the
development of preventive and therapeutic strategies against
filoviruses is our limited understanding of the function of
these proteins and the molecular details of the interaction of
filoviruses and infected host cells.
The key for development of effective adaptive immunity
to pathogens is rapid detection of a microbial presence and
the subsequent activation of the host innate immune response.
In recent years, dendritic cells (DCs) have been identified as a
central cell for both activation of innate immune responses
and initiation of adaptive immunity. DCs initiate immunity
via a variety of pathways including secretion of a broad array
of immunoregulatory molecules, presentation of antigen to B
and T lymphocytes, interactions with natural killer cells, and
direct cytotoxic activity against target cells (Lipscomb and
Masten, 2002; Liu, 2001; Steinman, 2001). Following expo-
sure to a pathogen or microbial-derived product, DCs under-
go maturation and activation, which is indicated by
phenotypic changes in specific cell-surface markers and
secretion of large amounts of cytokines and chemokines
(Liu, 2001). This maturation and activation process is vital,
as it serves to make DCs one of the most efficient antigen-
presenting cells in the body (Steinman, 2001).
We and others have shown that EBOV and MARV
readily infect DCs and replicate logarithmically (Bosio et
al., 2003; Geisbert et al., 2003; Mahanty et al., 2003).
However, despite this impressive invasion and replication,
filovirus-infected DCs fail to undergo phenotypic or func-
tional maturation, as indicated by the absence of changes in
cell-surface markers, lack of cytokine secretion, and inter-
ference with a mixed lymphocyte response (Bosio et al.,
2003; Mahanty et al., 2003). Filovirus-infected DC likely do
not appropriately initiate NK, B, and T-cell responses
following EBOV or MARV infection in vivo, resulting in
uncontrolled and disseminated infection of the host. At this
time, the mechanism by which EBOVand MARVefficiently
replicate in DC in the absence of stimulating immune
responses is not understood. However, the interaction be-
tween DC and filoviruses may be a target for development
of therapeutics for treating these devastating infections.
Recently, our laboratory reported that expression of both
filovirus glycoprotein (GP) and the VP40 matrix protein
leads to self-assembly of the viral proteins into filamentous
virus-like particles (VLPs) with morphological similarity to
filoviruses, but do not contain the viral genes necessary for
replication (Bavari et al., 2002; Swenson et al., 2004).
Importantly, the filovirus-like particles retain a morphology
and antigenicity that is indistinguishable from native virus
(Bavari et al., 2002; Swenson et al., 2004; Warfield et al.,
2003). These two properties make VLPs attractive candi-
dates for vaccine use, as well as tools for the study of virus/
immune cell interactions. On the basis of previous observa-
tions with VLPs (Lenz et al., 2001; Marais et al., 1999;Murata et al., 2003; Warfield et al., 2003), we hypothesize
that unlike authentic EBOV and MARV, Ebola (e) and
Marburg (m) VLP activate both innate and adaptive immu-
nity. The objective of our current study was to determine the
effects of eVLP and mVLP on human DCs. In this report,
we show that filovirus VLPs are taken up by DCs and
stimulate efficient maturation of human myeloid DCs, as
indicated by changes in the cell-surface expression of CD40,
CD80, CD83, CD86, MHC I, MHC II, CCR5, and CCR7
and by secretion of specific chemokines and pro-inflamma-
tory cytokines including interleukin (IL)-6, IL-8, macro-
phage inflammatory protein (MIP)-1a, and tumor necrosis
factor (TNF)-a. Therefore, unlike EBOV and MARV, filo-
virus VLPs composed solely of GP and VP40 stimulates
DCs. Together with our previous findings, these data
indicate that activation and maturation of DCs by filovirus
VLPs result in generation of both innate and adaptive
immune responses.Results and discussion
Ectopic expression of two filovirus proteins, VP40 and
GP, resulted in formation of VLPs morphologically indis-
tinguishable from EBOV and MARV (Bavari et al., 2002;
Swenson et al., 2004). Additionally, we recently showed
that injection of eVLP or mVLP completely protects rodents
from homologous filovirus infection (Warfield et al., 2004,
in press). The mechanisms of protection by the VLPs are
unknown at this point in time. Development of a successful
vaccine in higher primates is dependent upon knowledge of
the requirements for protective immunity. It has been
suggested that previous attempts to develop filovirus vac-
cines have failed in higher primates precisely due to this
lack of understanding (Hart, 2003). Hence, our primary goal
is to identify how the VLPs initiate immune responses and
how this immunogenicity in specific cell types might aid in
promoting lasting adaptive immune responses against
EBOV and MARV. Antigen-presenting cells (APCs) are
among the first immune cells to respond to viruses. Among
APCs, DCs are the most efficient at initiating antigen-
specific immune responses (Steinman, 2001). In their im-
mature state, DCs reside in peripheral tissues where they
continuously sample the environment and capture incoming
pathogens. To determine if DCs were capable of internaliz-
ing VLPs, immature DCs were incubated with DiIC16-
labeled VLPs and the cells examined by confocal micros-
copy for fluorescent VLPs within DCs. Both eVLP- and
mVLP-labeled particles were found inside DCs within 2
h (Fig. 1). Examination of successive optical planes (taken
at 0.5 Am intervals) confirmed that VLPs were within the
cells and not merely attached to the surface. To confirm that
the particles visualized within the DCs were indeed VLPs
and not extraneous cellular debris, VLPs were depleted from
preparations by a combination of antibodies against Ebola
or Marburg glycoprotein (GP). Following this depletion, we
Fig. 1. Uptake of Ebola and Marburg VLPs by human DCs. DCs were stained with CellTracker Green and Hoescht nuclear stain. VLPs were stained with
DiIC16 red dye. DCs were incubated for 2 h with the VLPs and unbound VLPs were washed away. VLP internalization was visualized by confocal microscopy
as described in Materials and methods. VLPs are illustrated as large aggregates inside DCs. These images represent five experiments of similar design and
outcome.
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shown), confirming that the DiIC16-labeled particles were
indeed VLPs.
Uptake of foreign particles by DCs is not sufficient for
inducing their maturation and subsequent contribution
toward immunity against a pathogen. Maximal stimula-
tion requires specific recognition and interaction between
the pathogen and the DC (Lanzavecchia, 1999). Human
myeloid DCs are readily infected by EBOV and MARV
and infected DCs produce large titers of virus shortly
following infection (Bosio et al., 2003; Mahanty et al.,Fig. 2. Effect of VLP-induced phenotypic maturation of DCs and modulate chem
10 Ag of eVLPs or mVLPs (solid black line). Controls were DCs treated with
represent staining with an appropriate isotype-matched, control antibody. The cel
CD86 (B7.1), CD40, CD11c, HLA-DR, HLA-ABC, and CD83 were analyzed b
design and results.2003). However, DCs infected with filoviruses show little
sign of sensing the viruses and infected DCs do not
become mature or activated (Bosio et al., 2003; Mahanty
et al., 2003). In striking contrast to live filoviruses,
exposure of DCs to filovirus-like particles induced DC
maturation (Fig. 2). Following VLP exposure, DCs in-
creased expression of cell-surface costimulatory molecules
including those essential for optimal activation of T cells:
CD40, CD80 (B7.1), CD83, and CD86 (B7.2). Cell-
surface receptors important for antigen presentation, such
as major histocompatibility class I (HLA-ABC) and classokine receptors CCR5 and CCR7. DCs (106 cells/ml) were incubated with
10 ng LPS (Dashed line), or medium alone (gray line). Filled histograms
ls were harvested at 24 h post-inoculation and expression of CD80 (B7.1),
y flow cytometry. Data are representative of three experiments of similar
C.M. Bosio et al. / Virology 326 (2004) 280–287 283II (HLA-DR) antigens, were upregulated on VLP-exposed
DCs, as well as the cell adhesion molecule CD11c.
Phenotypic maturation of DCs pulsed with VLPs was
similar to that observed in DCs incubated in the presence
of lipopolysaccharide (LPS), a known and potent stimu-
lator of DC maturation in vivo and in vitro (Fig. 2).
As an additional measure of phenotypic DC maturation,
it is critical to assess changes in specific chemokine
receptors present on DCs. During the DC maturation
process, there is small but measurable downregulation of
the chemokine receptor CCR5, combined with the more
obvious increased expression of CCR7. This coordinate
regulation of chemokine receptors is presumed to enhance
their ability to migrate from the afflicted tissue to resident
lymph nodes (Jarrossay et al., 2001). Sustained expression
of CCR7 allows DCs to perform their stepwise migration
from tissue to the regional lymph node. The essential role
of CCR7 in DC homing to lymphoid organs is supported
by the observation that in CCR7-deficient mice, maturing
DC are not able to migrate to lymph nodes (Fo¨rster et al.,
1999). Thus, changes in these two chemokine receptors, in
addition to other cell-surface markers discussed above, is
essential for optimal DC function in the ensuing immune
response. In support of the VLPs’ ability to induce
phenotypic maturation, we observed decreased surface
expression of CCR5 and increased surface expression of
CCR7 (Fig. 2). Interestingly, mVLP induced greater ex-
pression of CCR7 than eVLP 24 h poststimulation andFig. 3. Ebola and Marburg VLPs induce secretion of pro-inflammatory cytokin
incubated with 10 Ag eVLPs or mVLPs, replication-deficient Venezuelan equine
LPS, or medium only (mock). Concentration of each cytokine in duplicate culture s
described in the Materials and methods. These results are representative of threesustained greater CCR7 expression than LPS-stimulated
and eVLP-stimulated DCs 48 h after exposure, although
inactivated virus preparation failed to induce DC modula-
tion of CCR5 or CCR7 (data not shown). Although
downregulation of chemokine receptor CCR5 expression
on DCs was observed, the differences in CCR5 expression
among mock-, LPS-, VLP-stimulated, and inactivated virus
were not remarkable.
In addition to phenotypic maturation, DCs should also
undergo functional maturation to stimulate optimal innate
and adaptive immune responses (Liu, 2001). To assess
functional maturation, supernatants from VLP-treated DCs
were analyzed overtime for a panel of cytokines and
chemokines essential for potentiation of effective immune
responses. In contrast to responses previously observed
with infectious filoviruses, Ebola and Marburg VLPs
induced secretion of IL-6, IL-8, MIP-1a, and TNF-a
(Fig. 3). To confirm that the secretion of cytokines from
DCs was a specific result of VLPs interacting with DCs,
preparations were depleted of VLPs using antibodies
against EBOV or MARV GP. DCs incubated with these
depleted preparations did not secrete cytokines or upregu-
late cell-surface markers (data not shown). As a control for
nonspecific activation of the DC by any particle, we used
inactivated filoviruses or inert latex beads. In contrast to
the VLPs, neither inactivated EBOV or MARV nor latex
beads elicited DC secretion of any of the cytokines we
tested (unpublished data).es and chemotactic cytokines from human DCs. DCs (106 cells/ml) were
encephalitis replicons (VRP) encoding EBOV GP (m.o.i. of 1.0), 10 ng of
upernatants was measured at 2, 6, 18, and 24 h after addition of stimulant as
experiments of similar design and results.
Fig. 4. VLP protein structure, not LPS contamination, is responsible for the functional responses of DCs to eVLPs. To determine whether LPS contamination
was responsible for the DC cytokine secretion following VLP exposure, 10 Ag/ml polymyxin B was incubated eVLPs or LPS at room temperature. To
determine whether the protein structure of the eVLPs were responsible for the biological responses of the DCs to VLPs, either VLPs or LPS were subjected to
boiling at 100 jC. Equivalent amounts of VLPs and LPS were mock-treated. Following 1 h of the indicated treatment, 10 Ag/ml of VLPs or 10 ng/ml of LPS
were added to DCs, as above. The DC supernatants were removed after 18 h and analyzed by CBA for IL-6 and TNF-a. These results are representative of two
experiments of similar design and outcome.
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examined here could be also potentiated by endotoxin, we
added polymyxin B, a compound that binds and inactivatesFig. 5. Marburg and Ebola VLP enhance allogenic T-cell stimulation. One million
or Marburg virus, 10 ng of LPS, or mock-treated for 24 h. Subsequently, DCs we
(2.5  105 per/well) for 4 days. T-cell proliferation was assayed by [3H]thymid
independent experiments. Statistically significant differences ( P V 0.05) were dLPS biological functions (Jacobs and Morrison, 1977) to the
VLPs and reexamined DC responses to polymyxin B-treated
VLPs. We observed no alteration in the cytokine or chemo-DCs were stimulated with 10 Ag eVLP or mVLP, 50 Ag of inactivated Ebola
re washed and cocultured at graded numbers with purified allogenic T cells
ine incorporation. The results are expressed as mean CPM F SD of two
etermined between the VLP-treated and inactivated virus-treated groups.
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although addition of polymyxin B to LPS inhibited cytokine
production by DC (Fig. 4). Furthermore, boiling the VLPs,
which destroys VLP protein structure, significantly
inhibited the cytokine-inducing activity of the VLP. As
expected, boiling of LPS had no effect on the cytokine-
inducing activity of the VLP-stimulated DCs. Hence, the
protein structure of the VLPs, and not LPS contamination,
are the cause of the biological responses seen in VLP-
exposed DCs. Together, these data indicated that the filovi-
rus-like particles, in contrast to live filoviruses, specifically
interacted with human dendritic cells to induce their matu-
ration and activation.
Mature DCs are the most efficient cell for induction of
activation, differentiation, and proliferation of unprimed T
cells. EBOV and MARV interfere with DC-mediated T-cell
proliferation; thus, we investigated the effect of VLP-pulsed
DCs on T-cell proliferation in an allogenic mixed lympho-
cyte response (MLR). DCs were incubated for 24 h with
eVLP, mVLP, inactivated EBOV (iEBOV), or inactivated
MARV (iMARV). Allogenic T cells were then added to
treated DCs. Unlike iEBOV or iMARV, DCs pulsed with
eVLP or mVLP induced significant T-cell proliferation (Fig.
5; P < 0.001). Therefore, although native EBOVand MARV
did not support the ability of DC to induce proliferation of T
cells, VLP-stimulated DCs efficiently promoted primary T-
cell proliferative responses, likely due to the upregulation of
costimulatory and major histocompatibility molecules on
the activated DCs (Fig. 2).
EBOV, live or inactivated, interfere with or avoid DC
responses (Figs. 2 and 3; Bosio et al., 2003; Mahanty et al.,
2003). The specific protein(s) responsible for this interfer-
ence have not been fully identified. In the study presented
here, we have attempted to identify how VLPs might
successfully modulate DC immune responses. Although
EBOV GP has been proposed to modulate host adaptive
immune responses (Feldmann et al., 1999), we have com-
prehensively demonstrated that eVLP, which consists only
of GP and VP40, activate DCs. This suggests that GP
presented in conjunction with VP40 in particle form prob-
ably is not responsible for downregulation or interference of
DC responses to EBOV. Based on the data that are presented
here, it seems that VP40 is also not responsible for down
modulation of the DC response to filovirus infection. When
expressed alone, VP40 is spontaneously released from cells
(Jasenosky et al., 2001; Timmins et al., 2001). However,
studies within our laboratory show that the release of
filamentous structures by mere expression of VP40 was
far less efficient compared with cells transfected with both
GP and VP40 (unpublished data). Furthermore, the matrix
protein VP40 is not thought to be exposed on the virus
surface, and VP40 particle structures lack the typical spikes
of the filoviruses (Jasenosky et al., 2001; Timmins et al.,
2001). The importance of immune responses to VP40 are
questionable because administration of VP40 alone cannot
completely protect mice from lethal EBOV challenge, norguinea pigs from lethal MARV challenge (unpublished data
and Hevey et al., 1998; Wilson et al., 2001). Another
candidate for modulation of the DC responses following
filovirus infection is the IFN antagonist VP35. EBOV VP35
can block the phosphorylation and dimerization of the
transcription factor interferon regulatory factor 3, which
prevents activation of critical antiviral genes (Basler et al.,
2000, 2003; Bosio et al., 2003). Although the specific
mechanisms are unclear at this time, the virulence of EBOV
and MARV likely depends on their ability to evade or
downregulate the innate immune cell responses to viral
infections, especially early responders such as DCs. VLPs
with additional structural proteins, such as VP35, incorpo-
rated may allow us to dissect the immunomodulatory role of
individual virion components.
Previously, we reported that eVLP induced maturation
and activation of mouse bone marrow-derived DCs.
Injection of eVLP activated both B and T lymphocytes
within 3 days and eVLP vaccination of mice resulted in
complete protection against lethal EBOV challenge (War-
field et al., 2003). Similarly, mVLP vaccination of guinea
pigs induced MARV-specific antibody and T-cell
responses that protected from lethal MARV infection
(Warfield et al., 2004, in press). In this report we utilized
filovirus VLP as a tool to identify the immunogenic
nature of particles consisting of GP and VP40 in human
DCs. We showed activation and maturation of human
myeloid DCs by filovirus VLPs, which can result in
stimulation of primary T-cell responses. This work sup-
ports further testing of VLP as vaccine candidates and
suggests immunogenicity in humans. Beyond their appli-
cation as vaccines, the immunogenicity of Ebola and
Marburg VLP in human DC described herein also points
toward their usefulness and informative application in the
understanding of filovirus interaction with multiple com-
ponents of the host immune response. These types of
efforts should ultimately lead to better understanding of
filovirus pathogenesis.Materials and methods
Generation of Ebola and Marburg virus-like particles
Filovirus VLPs were generated as previously described
(Bavari et al., 2002). Briefly, cDNAs encoding Ebola virus
strain Zaire 1995 (EBOV) or Marburg virus strain Musoke
(MARV) GP and the corresponding matrix protein VP40
were cloned into the mammalian expression vector
pWRG7077. 293T cells were transfected using Lipofect-
amine 2000 according to manufacturer’s instructions (Invi-
trogen, Carlsbad, CA). VLPs were collected from cell-free
supernatants by an initial high-speed centrifugation fol-
lowed by purification on sucrose gradients. Confirmation
of the presence of VLPs and their quality was performed
using protein quantification, electron microscopy, Western
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previously described (Bavari et al., 2002; Swenson et al.,
2004; Warfield et al., 2004, in press) All VLP preparations
were tested for endotoxin using a LAL assay (BioWhittaker,
Walkersville, MD) and were found to be <0.03 IU endo-
toxin/Ag total protein.
Culture of primary human DCs
Primary adherent human monocytes were isolated fol-
lowing enrichment of peripheral blood monocytes by cen-
trifugation over ficoll-hypaque and resuspended in complete
(c) RPMI-1640 (LifeTechnologies, Rockville, MD) supple-
mented with 2 mM L-glutamine (Life Technologies, Grand
Island, NY), 10 mM HEPES buffer (Life Technologies), and
1% nonessential amino acids (NEAA, Life Technologies).
Cells were allowed to adhere (2 h at 37 jC) after which
nonadherent cells were removed. The adherent cells were
cultured in cRPMI-1640 supplemented with 100 ng/ml of
recombinant human GM-CSF (rhGM-CSF) and 20 ng/ml of
recombinant human IL-4 (rhIL-4) (both from R&D Sys-
tems, Minneapolis, MN). One-third of the medium and
100% of each cytokine were replaced every other day until
use. The resulting differentiated DC were >97% CD1a
positive and <1% CD14 negative. Immature DCs were used
on the fourth day of culture.
Staining of VLPs and confocal imaging
VLPs were incubated with the lipophilic dye DiIC16
(Molecular Probes, Eugene, OR) diluted 1:5000 in PBS for
10 min at room temperature. Unincorporated dye was
removed following addition of PBS and centrifugation.
Before addition of stained VLPs, DCs were incubated with
CellTracker Green CMFDA (Molecular Probes) for 1 h in
which the last 10 min Hoescht nuclear stain (Molecular
Probes) was also added. DCs were incubated with VLPs at
37 jC/5% CO2 for 2 h before visualization using a Radiance
2000 MP multiphoton confocal microscope with LaserSharp
2000 Software (Bio-Rad, Hercules, CA).
Stimulation of DCs
DCs (1  106 cells) were incubated with 10 Ag Ebola or
Marburg VLP, 50 Ag of irradiated (1.0  107 rad) EBOVor
MARV, 10 ng/ml lipopolysaccharide (LPS, Sigma, St.
Louis, MO), or replication-deficient Venezuelan equine
encephalitis replicons encoding EBOV GP (VRP) as previ-
ously described (Pushko et al., 2000). Briefly, immature
human DCs were incubated with VRP, VLP, VLP prepara-
tions depleted of VLPs using anti-GP antibodies, LPS, or
mock-infected at 5  105 DCs per well in 24-well plates. In
some assays, 10 Ag/ml polymyxin B was incubated with 10
Ag/ml of VLPs or 10 ng/ml LPS at room temperature for 1
h. Alternately, equivalent amounts of VLPs and LPS were
mock-treated or were subjected to boiling at 100 jC for 1 h.Following treatment, the VLPs or LPS were added to DCs,
as above. At designated time points, supernatants were
removed and frozen at 70 jC until analysis of cytokines
could be performed. At the designated time points, DCs
were stained for specific cell-surface markers and analyzed
by flow cytometry as described below.
Assay of cytokines in DC culture supernatants
Culture supernatants were assayed for MIP-1a using
Biosource kits (Camarillo, CA) or TNF-a, IL-6, and IL-
8 using cytometric bead array (Pharmingen, San Diego,
CA). Assays and controls conformed to the manufacturer’s
instructions.
Flow cytometry
Dendritic cell-surface markers were analyzed by flow
cytometry as previously described (Sallusto and Lanza-
vecchia, 1994). Briefly, cells were washed in cold PBS
supplemented with 2% fetal bovine serum and cell-
surface staining was done using the following antibodies:
fluorescein isothiocyanate (FITC)-conjugated anti-CCR5,
FITC-conjugated anti-CCR7, phycoerythrin (PE)-conjugat-
ed anti-CD83, FITC-conjugated anti-CD80, PE-conjugated
anti-CD86, FITC-conjugated anti-HLA-DR, PE-conjugat-
ed anti HLA-ABC, FITC-conjugated anti-CD40, PE-con-
jugated anti-CD11c, FITC-conjugated anti-mouse IgG1
n,
and PE conjugated anti-mouse IgG2b
n (all from PharMin-
gen). After incubation with antibodies, cells were washed
and fixed with 10% buffered formalin and analyzed using
a FACScalibur flow cytometer (Becton Dickinson, San
Jose, CA) with CellQuest software (Becton Dickinson). A
minimum of 10,000 events were collected and analyzed
for each sample.
Allogenic T-cell proliferation
Human T cells were enriched from peripheral blood
mononuclear cells (PBMC) by negative selection using
Dynal T-cell negative isolation kit (Dynal Biotech, Nor-
way). Allogenic DCs stimulator cells were pulsed with 10
Ag/ml of VLPs, inactivated Ebola or Marburg virus
(m.o.i. of 10), LPS, or mock-infected for 24 h. DCs
(5  103/well) were subsequently washed, resuspended in
cRPMI that contained heat-inactivated human AB serum
(BioWhittaker), and added at graded doses to purified
responder T cells (2.5  105/well) in 96-well round-
bottom microtiter plates (Corning, Inc., Corning, NY) in
a total volume of 200 Al. Triplicate cultures were main-
tained at 37 jC/5% CO2 for 5 days, after which time T-
cell proliferation was measured by incorporation of
[3H]thymidine ([3H]TdR) (Amersham, Arlington Heights,
IL). Each well received 1 ACi [3H]TdR and was subse-
quently harvested 18 h later. Results are represented as
mean CPM F SD of triplicate wells.
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Data were analyzed using a paired Student’s t test, and
results were considered significant if P V 0.05.
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